Early histological transformation of follicular lymphoma to diffuse large B-cell lymphoma indicating adverse survival: A population-based analysis and validation

被引:0
|
作者
Li, Zi-Hua [1 ]
Zhang, Min-Yue [1 ]
Federico, Massimo [2 ]
Civallero, Monica [2 ]
Manni, Martina [3 ]
Alonso-Alvarez, Sara [4 ]
Hou, Jian [1 ,5 ]
Huang, Hong-Hui [1 ,5 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Hematol, Shanghai, Peoples R China
[2] Univ Modena & Reggio Emilia, Surg Med & Dent Dept, Morphol Sci Related Transplant Oncol & Regenerat M, Dermatol Unit, Modena, Italy
[3] Univ Modena & Reggio Emilia, Dept Med & Surg Sci Children & Adults, Modena, Italy
[4] Hosp Univ Cent Asturias, Insituto Invest Sanit Principado Asturias ISPA, Oviedo, Asturias, Spain
[5] 160 Pujian Rd, Shanghai 200127, Peoples R China
关键词
follicular lymphoma; histological transformation; diffuse large B-cell lymphoma; prognosis; population-based study; SINGLE-ARM; 1ST-LINE IMMUNOCHEMOTHERAPY; OPEN-LABEL; RISK; OUTCOMES; MULTICENTER; RITUXIMAB; ERA;
D O I
10.1002/cncr.35378
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: The histological transformation (HT) of follicular lymphoma (FL) is a crucial biological event. The study aimed to evaluate the incidence, clinicial characteristics, prognosis and impact of HT time on survival of FL transforming to diffuse large B-cell lymphoma in population-based large-scale cohorts. Methods: A retrospective cohort study of FL with HT was performed in the Surveillance, Epidemiology, and End Results database. The Hematological Malignancy Research Network FL cohort and Aristotle study FL cohort were used to assess the external validity. Results: Among 44,127 FL cases from the Surveillance, Epidemiology, and End Results database, 1311 cases were pathology-proven recorded to transform to diffuse large B-cell lymphoma. The cumulative rates of HT at 5, 10, and 15 years after FL diagnosis were estimated to be 1.19%, 2.93%, and 5.01%, respectively. Significantly worse overall survival and cancer-specific survival were exhibited in patients with HT than those without HT. Early HT (transformation of FL within 48 months after FL diagnosis [TOD48]) was an independent predictor for adverse overall survival of HT patients, regardless of treatment modalities before transformation. The adverse prognostic effect of TOD48 was validated in the Hematological Malignancy Research Network cohort and Aristotle study cohort. Older age (>75 years) and B symptoms within FL at diagnosis were the independent risk factors of TOD48. Furthermore, a novel prognostic model combining TOD48 with Follicular Lymphoma International Prognostic Index (TOD48-FLIPI) was constructed and validated for risk stratification. Conclusion: TOD48 was a risk indicator of HT, and the novel prognostic model "TOD48-FLIPI" for HT patients was proposed.
引用
收藏
页码:3321 / 3332
页数:12
相关论文
共 50 条
  • [31] Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma
    Nastoupil, Loretta J.
    Kuruvilla, John
    Chavez, Julio C.
    Bijou, Fontanet
    Witzig, Thomas E.
    Santoro, Armando
    Flinn, Ian W.
    Boccomini, Carola
    Kenkre, Vaishalee P.
    Corradini, Paolo
    Isufi, Iris
    Andorsky, David J.
    Klein, Leonard M.
    Greenwald, Daniel R.
    Sangha, Randeep
    Shen, Frank
    Hagner, Patrick
    Li, Yan
    Dobmeyer, Juergen
    Gong, Nian
    Uttamsingh, Shailaja
    Pourdehnad, Michael
    Ribrag, Vincent
    EJHAEM, 2022, 3 (02): : 394 - 405
  • [32] Human Leukocyte Antigen Class I and II Alleles and Overall Survival in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
    Lu, Yani
    Abdou, Amr M.
    Cerhan, James R.
    Morton, Lindsay M.
    Severson, Richard K.
    Davis, Scott
    Cozen, Wendy
    Rothman, Nathaniel
    Bernstein, Leslie
    Chanock, Stephen
    Hartge, Patricia
    Wang, Sophia S.
    THESCIENTIFICWORLDJOURNAL, 2011, 11 : 2062 - 2070
  • [33] Primary breast diffuse large B-cell lymphoma: a population-based study from 1975 to 2014
    Jia, Yijun
    Sun, Chenbo
    Liu, Zebing
    Wang, Weige
    Zhou, Xiaoyan
    ONCOTARGET, 2018, 9 (03) : 3956 - 3967
  • [34] The use of tafasitamab in diffuse large B-cell lymphoma
    Duell, Johannes
    Topp, Max
    Salles, Gilles
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
  • [35] Primary mediastinal/thymic diffuse large B-cell lymphoma: a population-based study on incidence and survival
    Zhou, Huijie
    Liu, Qiuluo
    Lu, Siyan
    Zou, Liqun
    ANNALS OF HEMATOLOGY, 2023, 102 (07) : 1879 - 1886
  • [36] Non-Hodgkin Lymphomas: Impact of Rituximab on Overall Survival of Patients with Diffuse Large B-Cell and Follicular Lymphoma
    Carlos Jaime-Perez, Jose
    Magdalena Gamboa-Alonso, Carmen
    Vazquez-Mellado de larracoechea, Alberto
    Rodriguez-Martinez, Marisol
    Homero Gutierrez-Aguirre, Cesar
    Javier Marfil-Rivera, Luis
    Gomez-Almaguer, David
    ARCHIVES OF MEDICAL RESEARCH, 2015, 46 (06) : 454 - 461
  • [37] Primary breast diffuse large B-cell lymphoma in the era of rituximab
    Zhang, Na
    Cao, Caineng
    Zhu, Yuan
    Liu, Peng
    Liu, Luying
    Lu, Ke
    Luo, Jialin
    Zhou, Ning
    ONCOTARGETS AND THERAPY, 2016, 9 : 6093 - 6097
  • [38] Cardiovascular mortality among patients with diffuse large B-cell lymphoma: a population-based study
    Hong, Danhua
    Yin, Mengzhuo
    Li, Jie
    Deng, Zhiyong
    Ren, Zhilei
    Zhou, Yun
    Huang, Shuijin
    Yan, Xuejun
    Zhong, Weijie
    Liu, Feng
    Yang, Chongzhe
    LEUKEMIA & LYMPHOMA, 2024, 65 (11) : 1634 - 1644
  • [39] TRANSFORMATION OF INDOLENT LYMPHOMAS INTO DIFFUSE LARGE B-CELL LYMPHOMA
    Magomedova, A. U.
    Kovrigina, A. M.
    Mangasarova, Y. K.
    Kravchenko, S. K.
    Nikulina, E. E.
    Obukhova, T. N.
    Zvonkov, E. E.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2024, 69 (01): : 112 - 120
  • [40] Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit status
    Behdad, Amir
    Boddy, Craig S.
    Fought, Angela J.
    Taxter, Timothy
    Falkiewicz, Marissa K.
    Ayers, Emily
    Chen, Qing C.
    Chen, Yi-Hua
    Karmali, Reem
    Pro, Barbara
    Winter, Jane N.
    Landsburg, Daniel J.
    Gordon, Leo, I
    Kaplan, Jason B.
    LEUKEMIA & LYMPHOMA, 2019, 60 (13) : 3266 - 3271